RESUMEN
INTRODUCTION: Insulin lispro 100 units/mL Jr KwikPen is the first prefilled, disposable, half-unit insulin pen that delivers 0.5-30 units in increments of 0.5 units for the treatment of patients with diabetes. This study describes the profile of patients in Spain who initiated insulin therapy with Jr KwikPen in a real-world setting. METHODS: This retrospective, observational study based on IQVIA's electronic medical records database included patients with Type 1 (T1D) or Type 2 (T2D) diabetes who initiated therapy with Jr KwikPen between May 2018 and December 2020. Sociodemographic, clinical, and treatment characteristics at treatment initiation were analysed descriptively. RESULTS: A total of 416 patients were included. The main characteristics of the T1D/T2D groups (N = 326/90), respectively were as follows: female sex, 61.7%/65.6%; mean age (standard deviation [SD]), 32.5 (20.7)/55.5 (16.6) years; body mass index, 20.9 (4.2)/25.2 (4.6) kg/m2 (N = 239/77); HbA1c, 7.8 (1.7)%/8.0 (1.5)% (N = 141/64); and presence of diabetes-associated comorbidities, 27.9%/64.4%. Only 32.8% of patients with T1D were < 18 years old. Among Jr KwikPen users, 12.3% (T1D/T2D, 7.7%/28.9%) were ≥ 65 years old, 17.1% patients were newly diagnosed, and 3.8% were pregnant women. The mean (SD) total insulin dose pre-index for T1D/T2D was 43.1 (23.6) and 40.7 (21.6) UI/day, respectively. The mean (SD) insulin dose at the start of Jr KwikPen use was 26.63 (16.56) and 22.58 (13.59) UI/day for T1D/T2D, respectively. Jr KwikPen was first prescribed mainly by endocrinologists (58.7%) or paediatricians (22.6%). CONCLUSIONS: The profile of patients who initiated therapy with Jr KwikPen in routine practice was broad with many patients being adults. Most of these patients had T1D, inadequate glycemic control, and multiple associated comorbidities. These results suggest that Jr KwikPen is prescribed in patients who may benefit from finer insulin dose adjustments, namely children, adolescents, adults, older individuals, or pregnant women with T1D or T2D.
Asunto(s)
Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Adolescente , Adulto , Anciano , Niño , Femenino , Humanos , Embarazo , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes , Insulina , Insulina Regular Humana/uso terapéutico , Estudios Retrospectivos , España/epidemiología , Masculino , Adulto Joven , Persona de Mediana EdadRESUMEN
OBJECTIVES: Flash glucose monitoring in patients with type 1 diabetes provides new glucometric data that allow for the assessment of glycemic control beyond HbA1c. The objective of the study was to evaluate the relationship between HbA1c, time-in-range (TIR) and glycemic variability in a cohort of paediatric and adult patients with type 1 diabetes and treatment with flash glucose monitoring. MATERIAL AND METHODS: This was a cross-sectional study in 195 patients with type 1 diabetes (42.6% females, 70 paediatric, 26.2% continuous subcutaneous insulin infusion, 28.7% coefficient of variation [CV]≤36%) in intensive treatment and flash glucose monitoring. Clinical, analytical and glucometric data were evaluated. RESULTS: The relationship between the TIR and HbA1c showed a strong negative linear correlation (R=-0.746; R2=0.557; P<.001), modified in those patients with CV≤36% (R=-0.852; R2=0.836) compared to CV>36% (R=-0.703; R2=0.551). A similar correlation was found when evaluating the TIR and the Glucose Management Indicator (R=-0.846; R2=0.715; P<.001); in patients with CV≤36% (R=-0.980; R2=0.960) versus CV>36% (R=-0.837; R2=0.701); P<.001. Both correlations remained stable in the paediatric population (R=-0.724; R2=0.525; P<.001) and adults (R=-0.706; R2=0.498; P<.001) and by type of treatment: multiple doses of insulin (R=-0.747; R2=0.558; P<.001) and continuous subcutaneous insulin infusion (R=-0.711; R2=0.506; P<.001). In a multiple regression analysis evaluating HbA1c as dependent variable, the only parameters that maintained statistical significance were the TIR (ß=-0,031; P<.001), CV (ß=0.843; P<.05) and TIR-CV interaction (ß=-0.017; P<.01). CONCLUSIONS: The glycemic variability defined by the CV modifies the relationship between the TIR and HbA1c/Glucose Management Indicator and should be taken into account when individualising TIR targets, regardless of age or the type of treatment used.
Asunto(s)
Glucemia , Diabetes Mellitus Tipo 1 , Hemoglobina Glucada , Adulto , Glucemia/análisis , Automonitorización de la Glucosa Sanguínea , Niño , Estudios Transversales , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Femenino , Hemoglobina Glucada/análisis , Humanos , Insulina/uso terapéutico , MasculinoAsunto(s)
Humanos , Femenino , Niño , Calcio , Hipercalcemia/diagnóstico , Hipercalcemia/genética , HiperparatiroidismoRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Gestacional/tratamiento farmacológico , Insulina/administración & dosificación , Hipoglucemiantes/administración & dosificación , Resultado del Embarazo , Estudios Retrospectivos , Infusiones Subcutáneas , Trimestres del EmbarazoAsunto(s)
Hipercalcemia , Hiperparatiroidismo , Calcio , Humanos , Hipercalcemia/diagnóstico , Hipercalcemia/genéticaRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Niño , Diabetes Insípida/diagnóstico , Diabetes Insípida/genética , Mutación/genética , Diuresis , Polidipsia/complicaciones , Poliuria/complicaciones , Sobrepeso/complicaciones , Diabetes Insípida/tratamiento farmacológicoRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Niño , Trastorno Dismórfico Corporal/genética , Trastornos del Crecimiento/genética , Pruebas Genéticas/métodos , Trastornos Psicomotores/genéticaAsunto(s)
Aracnodactilia/diagnóstico , Craneosinostosis/diagnóstico , Pruebas Genéticas , Trastornos del Crecimiento/etiología , Síndrome de Marfan/diagnóstico , Aracnodactilia/complicaciones , Aracnodactilia/genética , Niño , Craneosinostosis/complicaciones , Craneosinostosis/genética , Femenino , Humanos , Síndrome de Marfan/complicaciones , Síndrome de Marfan/genéticaRESUMEN
Antecedentes y objetivo: El síndrome de Turner (ST) se asocia con talla baja, disgenesia gonadal y monosomía parcial o total del cromosoma X. Pacientes y métodos: Se realizó un estudio de cohortes histórico de las pacientes con ST≤18 años seguidas en los hospitales públicos de Castilla y León. Resultados: Se registraron 42 pacientes (diagnóstico prenatal 11,9%, neonatal 14,3%) con una edad media actual de 11,9±4,2 años. La talla baja fue el motivo de consulta en el 87,1%. El 40,5% presentaban monosomía total del cromosoma X. La enfermedad asociada más frecuente fue la oftalmológica (50%), con problemas cardiacos en el 23,8%. El 93% reciben tratamiento congrowth hormone (GH, «hormona de crecimiento»), con una edad media al inicio de 7,43±3,4 años y una DE media de talla de −2,84±1,08. Solamente 10 pacientes han alcanzado talla final (talla media 151,47±6,09cm). La edad cronológica media de inducción puberal fue 13,2 años±0,94 años (edad ósea 12,47±1,17). Conclusiones: Uno de los datos clave para el diagnóstico fue la talla baja acompañada en algunos casos de otros hallazgos, siendo el tratamiento con GH efectivo (AU)
Background and objective: Turner syndrome (TS) is characterized by short stature, gonadal dysgenesis, and total or partial loss of X chromosome. Patients and methods: A historical cohorts study of patients with TS≤18 years old followed up in public hospitals in Castilla y Leon was undertaken. Results: Forty-two female patients were included (prenatal diagnosis 11.9%, neonatal diagnosis 14.3%) with current median age 11.9±4.2 years. Short stature was the reason for consultation in 87.1%. Total monosomy of X chromosome was present in 40.5%. The most frequently associated comorbidity was opthalmological (50%), with heart defects in 23.8%. Ninety-three percent were treated with growth hormone (GH), mean age at the beginning of treatment was 7.43±3.4 years and mean height standard deviation was −2.84±1.08. Final height was reached in 10 patients only (mean final height 151.47±6.09cm). Chronological age of puberty induction was 13.2±0.94 years (bone age 12.47±1.17 years) (AU)
Asunto(s)
Humanos , Síndrome de Turner/epidemiología , Trastornos del Crecimiento/epidemiología , Hormona del Crecimiento/uso terapéutico , Diagnóstico Prenatal/estadística & datos numéricos , Cardiopatías Congénitas/epidemiología , Enfermedad Celíaca/epidemiologíaRESUMEN
BACKGROUND AND OBJECTIVE: Turner syndrome (TS) is characterized by short stature, gonadal dysgenesis, and total or partial loss of X chromosome. PATIENTS AND METHODS: A historical cohorts study of patients with TS≤18 years old followed up in public hospitals in Castilla y Leon was undertaken. RESULTS: Forty-two female patients were included (prenatal diagnosis 11.9%, neonatal diagnosis 14.3%) with current median age 11.9±4.2 years. Short stature was the reason for consultation in 87.1%. Total monosomy of X chromosome was present in 40.5%. The most frequently associated comorbidity was opthalmological (50%), with heart defects in 23.8%. Ninety-three percent were treated with growth hormone (GH), mean age at the beginning of treatment was 7.43±3.4 years and mean height standard deviation was -2.84±1.08. Final height was reached in 10 patients only (mean final height 151.47±6.09cm). Chronological age of puberty induction was 13.2±0.94 years (bone age 12.47±1.17 years). CONCLUSIONS: Short stature was an important clinical sign for the diagnosis of TS, accompanied in some cases by other findings, with good response to GH treatment.
Asunto(s)
Síndrome de Turner/diagnóstico , Adolescente , Niño , Preescolar , Femenino , Estudios de Seguimiento , Hormona del Crecimiento/uso terapéutico , Humanos , Lactante , Recién Nacido , Pronóstico , Estudios Retrospectivos , Síndrome de Turner/complicaciones , Síndrome de Turner/genética , Síndrome de Turner/terapiaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Niño , Eliminación de Gen , Síndrome de Deleción 22q11/diagnóstico , Síndrome de Deleción 22q11/tratamiento farmacológico , Síndrome de Deleción 22q11/genética , Hormona del Crecimiento/uso terapéutico , Hormona de Crecimiento Humana/uso terapéutico , Insuficiencia Velofaríngea/complicaciones , Imagen por Resonancia MagnéticaRESUMEN
No disponible